Financial markets are navigating a period of important transitions across asset classes. Gold (XAU/USD) is trading above the $5,000 level, holding near record highs as central bank accumulation and easing policy expectations collide with rising yield risks. Meanwhile, Moderna is shifting from pandemic-driven revenues toward a pipeline-focused growth model, as investors assess regulatory progress, ongoing losses, and the long-term value of its mRNA platform. In currency markets, NZD/USD remains trapped below the 0.60 psychological level, reflecting policy caution from the Reserve Bank of New Zealand and ongoing uncertainty surrounding US Federal Reserve decisions.
Together, these three assets highlight a broader theme: markets are balancing structural support with policy-driven uncertainty, where interest rates, inflation trends, and global risk sentiment remain the dominant forces shaping investor behavior.
Financial markets are navigating a period of important transitions across asset classes. Gold (XAU/USD) is trading above the $5,000 level, holding near record highs as central bank accumulation and easing policy expectations collide with rising yield risks. Meanwhile, Moderna is shifting from pandemic-driven revenues toward a pipeline-focused growth model, as investors assess regulatory progress, ongoing losses, and the long-term value of its mRNA platform. In currency markets, NZD/USD remains trapped below the 0.60 psychological level, reflecting policy caution from the Reserve Bank of New Zealand and ongoing uncertainty surrounding US Federal Reserve decisions.
Together, these three assets highlight a broader theme: markets are balancing structural support with policy-driven uncertainty, where interest rates, inflation trends, and global risk sentiment remain the dominant forces shaping investor behavior.
Gold Above $5,000: Record Highs Meet Policy and Yield Crosscurrents
As of mid-February 2026, XAU/USD is trading above the $5,000 level, holding near record territory after an exceptionally strong multi-year rally. Gold remains firmly in an upward trend on higher time frames, supported by sustained safe-haven demand and structural buying from central banks. Year-to-date performance remains positive, with prices consolidating rather than reversing after recent gains. Short-term volatility has increased, but importantly, pullbacks have been shallow — suggesting buyers are still stepping in on dips rather than exiting aggressively.
Momentum recently has been driven by softer US macro data, ongoing geopolitical uncertainty, and expectations that US monetary policy will gradually ease later this year. The US dollar has shown periods of consolidation, which have helped gold maintain elevated levels.
Gold Backed by Central Bank Buying, Tested by Yield Pressures
One of the strongest structural pillars for gold remains central bank accumulation. Institutions such as the People's Bank of China continue diversifying reserves into gold, reinforcing long-term demand. Emerging market central banks more broadly have maintained steady purchases as part of de-dollarization strategies.
Monetary policy expectations also remain supportive. Markets anticipate that the Federal Reserve will move toward a more accommodative stance later in 2026 if inflation continues to moderate. Lower rates reduce the opportunity cost of holding non-yielding assets like gold.
On the bearish side, risks remain. If inflation proves sticky and rate cuts are delayed, US Treasury yields could move higher again, pressuring gold. Additionally, strong equity performance can temporarily divert capital away from defensive assets. ETF flows have been uneven, suggesting that speculative positioning is not uniformly bullish.
Gold at a Crossroads: Central Bank Strength Meets Rate Uncertainty
Gold's valuation is tightly linked to real yields, inflation expectations, and the US dollar. Inflation has cooled from prior peaks but remains above the Federal Reserve's long-term 2% target, keeping policy decisions data-dependent. Markets currently expect gradual easing rather than aggressive cuts.
Geopolitical tensions — particularly involving Russia-Ukraine and Middle East dynamics — continue to underpin safe-haven demand. At the same time, elevated global debt levels and fiscal concerns in major economies reinforce gold's appeal as a store of value.
Currency movements are equally important. A weaker US dollar generally supports gold, while a sustained dollar rebound could slow upside momentum. Investors are closely watching real interest rates, as declines in inflation-adjusted yields tend to favor continued strength in precious metals.
Moderna at a Crossroads: From Pandemic Leader to Pipeline-Driven Growth Story
Moderna stands at a pivotal stage in its corporate evolution. After emerging as a global leader in mRNA technology during the pandemic, the company is now navigating a complex transition from COVID-driven revenues toward a broader, multi-product biotechnology platform. Investors are increasingly focused not only on near-term vaccine sales but also on regulatory clarity, cost discipline, and the long-term value of Moderna's expanding pipeline across respiratory diseases and oncology. The coming quarters will be critical in determining whether the company can stabilize earnings and translate its scientific platform into sustainable growth.
Moderna: Powering the Next Generation of Medicine Through mRNA Innovation
Moderna, Inc. is a biotechnology company and a leader in messenger RNA (mRNA) medicine, aiming to transform how diseases are prevented and treated by using mRNA technology to create medicines more quickly and efficiently. Its mRNA platform supports development across four main areas: respiratory virus vaccines, latent/other virus vaccines, oncology therapeutics, and rare disease therapeutics. Moderna's first commercial product is Spikevax (its COVID-19 vaccine), and in 2024, it became a multi-product company with approval of mRESVIA, an mRNA RSV vaccine for older adults. The company's principal corporate office is in Cambridge, Massachusetts.
Moderna Q4 2025: Revenue Stabilizes, Losses Persist as Post-Pandemic Reset Continues
On February 13, 2026, Moderna released its financial results for the fourth quarter and full year of 2025.
In the fourth quarter, the company generated $700 million in revenue but recorded a net loss of $800 million. For the full year, revenue reached $1.9 billion, while the company posted a net loss of $2.8 billion.
In simple terms, Moderna is still operating at a loss as COVID vaccine sales remain significantly lower than they were during the peak pandemic period.
Pipeline Progress: Global Flu Reviews Advance as Norovirus and Cancer Trials Move Forward
On the pipeline front, Moderna reported several important developments. Its influenza vaccine filings have been accepted for regulatory review in Europe, Canada, and Australia. However, the US FDA issued a Refusal-to-File letter, meaning the application requires additional clarification before the review process can proceed, and the company has requested a meeting to determine the next steps. Meanwhile, Moderna's Phase 3 norovirus vaccine trial is now fully enrolled, with key results expected in 2026. In oncology, a Phase 2 study in muscle-invasive bladder cancer has also completed enrollment, marking continued progress in the company's cancer pipeline.
Key Risks: Regulatory Hurdles, Pipeline Uncertainty, and Revenue Volatility
Moderna faces several key risks as it transitions beyond pandemic-driven revenues. The company remains heavily dependent on seasonal respiratory vaccine sales, which can fluctuate based on public demand and government policy. Regulatory uncertainty, particularly in the US following the FDA's Refusal-to-File letter for its flu vaccine, could delay product launches and impact future revenue growth. Continued net losses and high research and development spending also weigh on profitability, increasing pressure to successfully commercialize pipeline candidates. In addition, competition in vaccines and oncology is intense, and clinical trial setbacks or weaker-than-expected data could significantly affect investor confidence and valuation.
Technical Outlook for Moderna
From a technical perspective, Moderna's broader structure remains upward, with recent price action suggesting continuation of the bullish trend. The stock continues to trade above both the 20- and 50-period exponential moving averages, and the upward slope of these indicators points to a continued uptrend. Momentum signals support the bullish scenario: the Momentum oscillator remains above the 100 threshold, reflecting bullish pressure, while the Relative Strength Index holds above 50, indicating that buyers still maintain a near-term advantage.
At the time of writing, Moderna is trading near 49.78. Immediate resistance is located at 55.08, followed by 66.31 and 84.48. On the downside, initial support stands at 43.00; a decisive break below this level would likely expose 36.53. In a more pronounced corrective scenario, the 28.95 area could come into focus, where stronger buying interest may emerge to stabilize the broader structure
Outlook: Modest Growth Ahead as Pipeline Catalysts Shape Moderna's Next Chapter
Moderna's 2026 outlook reflects a cautious rebuilding phase. The company expects revenue to grow by up to 10% in 2026, supported mainly by its respiratory vaccine portfolio, while continuing efforts to reduce operating expenses. Management has also indicated that cash levels are expected to remain solid despite ongoing research and development investment. Near-term performance will depend on seasonal COVID and RSV sales and regulatory progress on the influenza program. Longer term, key clinical readouts — particularly in oncology — could play a decisive role in restoring stronger, sustainable growth.
NZD/USD Trapped Below 0.60 as RBNZ Caution and Fed Uncertainty Collide
The NZD/USD pair is currently trading around 0.5980, meaning one New Zealand dollar buys about 0.598 US dollars.
Earlier this month, the pair staged a modest rebound, but it has since settled into a consolidation phase just below the key 0.60 psychological level, where buying momentum has struggled to build.
Price action has been uneven, with advances often losing steam as traders react to incoming economic data from both New Zealand and the United States.
Overall, the tone remains cautiously neutral, with volatility increasing at times due to policy headlines and shifting expectations around US dollar strength.
NZD/USD Stalls Below 0.60 as Policy Divergence Keeps Traders Cautious
On the New Zealand dollar side, the Reserve Bank of New Zealand kept its official cash rate unchanged at 2.25%, maintaining an accommodative stance and signaling that any rate hikes are likely to be pushed into late 2026 or even later.
This cautious tone weighed on the NZD, as markets adjusted their expectations for future tightening, reducing the currency's near-term yield appeal compared with the US dollar.
At the same time, domestic indicators such as retail sales have shown pockets of resilience, suggesting the economy is not weak, but still not strong enough to justify a more aggressive policy shift.
On the US dollar side, attention remains focused on economic data and Federal Reserve policy expectations, which continue to play a key role in shaping the direction of NZD/USD.
Dollar Uncertainty Keeps NZD/USD on an Uneven Path
On the US dollar side, developments in trade policy, including recent Supreme Court tariff rulings, have at times weighed on the dollar by improving overall risk sentiment and reducing demand for safe-haven assets.
Economic data has delivered mixed signals, leaving markets uncertain about whether the Federal Reserve will move ahead with aggressive rate cuts later this year, especially as some indicators continue to point to lingering inflation pressures.
Because NZD/USD is highly sensitive to broader dollar trends, periods of USD weakness tend to lift the pair, while renewed dollar strength typically pushes it lower.